A groundbreaking new test can accurately diagnose drug-resistant tuberculosis (TB) in as little as two hours, researchers wrote in a study published Thursday in the New England Journal of Medicine.
The test -- remarkable not only for its ease-of-use and accuracy, but its cost-effectiveness -- works on the molecular level, identifying genetic markers for the illness in the saliva of test subjects.
Researchers said the result is a far quicker diagnosis than when using traditional testing methods.
"Early, rapid and accurate detection of TB, including identification of drug-resistant strains, is critical to effectively treating the disease, reducing secondary resistance, stopping further transmission and saving lives," said Giorgio Roscigno, chief executive officer of the Foundation for Innovative New Diagnostics (FIND), one of the funders of the research.
The milestone, he said, can "help save the millions of lives needlessly lost to TB every year."
The test not only detects the presence of TB, but also identifies whether it is the strain of the disease that is resistant to rifampin -- a frontline medication used to treat the illness.
Of 1,730 patients suspected to have drug resistant TB, the test was able to correctly identify 98 percent.
"The need for accurate and rapid detection of tuberculosis for the growing at-risk populations in the developing world has been well-documented," said John Bishop, Cepheid, the company which developed the molecular diagnostic exam.
Experts say a speedy diagnosis of TB, particularly the drug-resistant variant, is especially vital in sub-Saharan Africa and Southeast Asia because of the close connection between HIV and TB.